SPRYCEL Drug Patent Profile
✉ Email this page to a colleague
When do Sprycel patents expire, and when can generic versions of Sprycel launch?
Sprycel is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has forty-seven patent family members in twenty-nine countries.
The generic ingredient in SPRYCEL is dasatinib. There are fourteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dasatinib profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sprycel
A generic version of SPRYCEL was approved as dasatinib by APOTEX on June 10th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SPRYCEL?
- What are the global sales for SPRYCEL?
- What is Average Wholesale Price for SPRYCEL?
Summary for SPRYCEL
International Patents: | 47 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 139 |
Clinical Trials: | 178 |
Patent Applications: | 4,294 |
Drug Prices: | Drug price information for SPRYCEL |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SPRYCEL |
What excipients (inactive ingredients) are in SPRYCEL? | SPRYCEL excipients list |
DailyMed Link: | SPRYCEL at DailyMed |
Recent Clinical Trials for SPRYCEL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fernando De la Garza Salazar | Phase 2 |
Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
Odense University Hospital | Phase 2 |
Pharmacology for SPRYCEL
Drug Class | Kinase Inhibitor |
Mechanism of Action | Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors |
US Patents and Regulatory Information for SPRYCEL
SPRYCEL is protected by two US patents and four FDA Regulatory Exclusivities.
Patents protecting SPRYCEL
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting SPRYCEL
TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-006 | Oct 28, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-004 | May 30, 2008 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-006 | Oct 28, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-004 | May 30, 2008 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-001 | Jun 28, 2006 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SPRYCEL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-002 | Jun 28, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-006 | Oct 28, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-002 | Jun 28, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-001 | Jun 28, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-004 | May 30, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SPRYCEL
See the table below for patents covering SPRYCEL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 20014970 | ⤷ Sign Up | |
Malaysia | 139730 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | ⤷ Sign Up |
China | 1980909 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | ⤷ Sign Up |
Japan | 5148115 | ⤷ Sign Up | |
Poland | 1711481 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SPRYCEL
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1169038 | 13C0003 | France | ⤷ Sign Up | PRODUCT NAME: DASATINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/06/363/001 20061122 |
1169038 | 122013000012 | Germany | ⤷ Sign Up | PRODUCT NAME: DASATINIB UND PHARMAZEUTISCH GEEIGNETE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-009 EU/1/06/363/010-011 EU/1/06/363/012-015 20061120 |
1169038 | 2013/003 | Ireland | ⤷ Sign Up | PRODUCT NAME: DASATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120 |
1169038 | 300567 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 - 009 20061120 |
1169038 | CA 2013 00006 | Denmark | ⤷ Sign Up | PRODUCT NAME: DASATINIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER MONOHYDRATET; REG. NO/DATE: EU/1/06/363/001-015 20061122 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |